An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 187-201

  Tu, Chengjian ^a   Li, Jun ^a   Bu, Yahao ^a   Hangauer, David ^a   Qu, Jun ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anti cancer drugs; Drug mechanism of action; Drug responsive proteomics signatures; False positive biomarker discovery rate; Peptide ion current areas

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; KX 01; KX 02; PROTEIN KINASE P60; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FALSE POSITIVE RESULT; HUMAN; HUMAN CELL; IMMUNOASSAY; ION CURRENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEOMICS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEOMICS;

EID: 84870390546     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.08.020     Document Type: Article

References (68)

1. Sivachenko A.Y., Yuryev A. Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism. Expert Opin Ther Targets 2007, 11:411-421.
2. Nowatzke W., Cole T.G., Bowsher R.R. Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development. Bioanalysis 2010, 2:237-247.
3. Schacke H., Docke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002, 96:23-43.
4. Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003, 348:618-629.
5. Muroi M., Kazami S., Noda K., Kondo H., Takayama H., Kawatani M., et al. Application of proteomic profiling based on 2D-DIGE for classification of compounds according to the mechanism of action. Chem Biol 2010, 17:460-470.
6. Staunton J.E., Slonim D.K., Coller H.A., Tamayo P., Angelo M.J., Park J., et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001, 98:10787-10792.
7. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10:321-330.
8. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357.
9. Nishizuka S., Charboneau L., Young L., Major S., Reinhold W.C., Waltham M., et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003, 100:14229-14234.
10. Shankavaram U.T., Reinhold W.C., Nishizuka S., Major S., Morita D., Chary K.K., et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007, 6:820-832.
11. Stevens E.V., Nishizuka S., Antony S., Reimers M., Varma S., Young L., et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008, 7:10-18.
12. Tian Q., Stepaniants S.B., Mao M., Weng L., Feetham M.C., Doyle M.J., et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 2004, 3:960-969.
13. Ma Y., Ding Z., Qian Y., Shi X., Castranova V., Harner E.J., et al. Predicting cancer drug response by proteomic profiling. Clin Cancer Res 2006, 12:4583-4589.
14. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035-1044.
15. Lilley K.S., Razzaq A., Dupree P. Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. Curr Opin Chem Biol 2002, 6:46-50.
16. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
17. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17:994-999.
18. DeSouza L., Diehl G., Rodrigues M.J., Guo J., Romaschin A.D., Colgan T.J., et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2005, 4:377-386.
19. Wang G., Wu W.W., Zeng W., Chou C.L., Shen R.F. Label-free protein quantification using LC-coupled ion trap or FT mass spectrometry: reproducibility, linearity, and application with complex proteomes. J Proteome Res 2006, 5:1214-1223.
20. Higgs R.E., Knierman M.D., Gelfanova V., Butler J.P., Hale J.E. Label-free LC-MS method for the identification of biomarkers. Methods Mol Biol 2008, 428:209-230.
21. Oda Y., Huang K., Cross F.R., Cowburn D., Chait B.T. Accurate quantitation of protein expression and site-specific phosphorylation. Proc Natl Acad Sci U S A 1999, 96:6591-6596.
22. Duan X., Young R., Straubinger R.M., Page B., Cao J., Wang H., et al. A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J Proteome Res 2009, 8:2838-2850.
23. Domon B., Aebersold R. Options and considerations when selecting a quantitative proteomics strategy. Nat Biotechnol 2010, 28:710-721.
24. Calvo S.E., Mootha V.K. The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet 2010, 11:25-44.
25. Fruh V., IJzerman A.P., Siegal G. How to catch a membrane protein in action: a review of functional membrane protein immobilization strategies and their applications. Chem Rev 2011, 111:640-656.
26. Leth-Larsen R., Lund R.R., Ditzel H.J. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics 2010, 9:1369-1382.
27. Mueller L.N., Brusniak M.Y., Mani D.R., Aebersold R. An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. J Proteome Res 2008, 7:51-61.
28. Nilsson T., Mann M., Aebersold R., Yates J.R., Bairoch A., Bergeron J.J. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 2010, 7:681-685.
29. Ono M., Shitashige M., Honda K., Isobe T., Kuwabara H., Matsuzuki H., et al. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006, 5:1338-1347.
30. Carr S.A., Anderson L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?. Clin Chem 2008, 54:1749-1752.
31. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
32. Diamandis E.P. Cancer biomarkers: can we turn recent failures into success?. J Natl Cancer Inst 2010, 102:1462-1467.
33. Qu J., Lesse A.J., Brauer A.L., Cao J., Gill S.R., Murphy T.F. Proteomic expression profiling of Haemophilus influenzae grown in pooled human sputum from adults with chronic obstructive pulmonary disease reveal antioxidant and stress responses. BMC Microbiol 2010, 10:162.
34. Tu C., Li J., Young R., Page B.J., Engler F., Halfon M.S., et al. Combinatorial peptide ligand library treatment followed by a dual-enzyme, dual-activation approach on a nanoflow liquid chromatography/orbitrap/electron transfer dissociation system for comprehensive analysis of swine plasma proteome. Anal Chem 2011, 83:4802-4813.
35. Anbalagan M., Carrier L., Glodowski S., Hangauer D., Shan B., Rowan B.G. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Cancer Res Treat 2012, 132:391-409.
36. Michael J., Ciesielski S.A.M., Clements James L., Hangauer David G., Dyster Lyn M., Barnett Allen, et al. KX02, a novel therapeutic for glioma. Cancer Res 2010, 70(8 Suppl.). [Abstract nr 5598].
37. David G, Hangauer J. Compositions and methods of treating cell proliferation disorders, US Patents #7,300,931 B2 & 8,003,641. 2005.
38. Yahao Bu M.S., Qu Jun, Kazim Latif, Dyster Lyn, Gelman Irwin, Hangauer David Mechanism of action KX01 (KX2-391), a novel tubulin polymerization and Src signaling inhibitor proceeding to Phase II clinical trials. 101st AACR Annual Meeting (Abstract #2487) 2010, [Washington, DC].
39. Elias J.E., Haas W., Faherty B.K., Gygi S.P. Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods 2005, 2:667-675.
40. Searle B.C. Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies. Proteomics 2010, 10:1265-1269.
41. Lopez M.F., Kuppusamy R., Sarracino D.A., Prakash A., Athanas M., Krastins B., et al. Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum. J Proteome Res 2011, 10:133-142.
42. Sadygov R.G., Maroto F.M., Huhmer A.F. ChromAlign: a two-step algorithmic procedure for time alignment of three-dimensional LC-MS chromatographic surfaces. Anal Chem 2006, 78:8207-8217.
43. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
44. de Hoon M.J., Imoto S., Nolan J., Miyano S. Open source clustering software. Bioinformatics 2004, 20:1453-1454.
45. Kashino Y. Separation methods in the analysis of protein membrane complexes. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 797:191-216.
46. Old W.M., Meyer-Arendt K., Aveline-Wolf L., Pierce K.G., Mendoza A., Sevinsky J.R., et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005, 4:1487-1502.
47. Dicker L., Lin X., Ivanov A.R. Increased power for the analysis of label-free LC-MS/MS proteomics data by combining spectral counts and peptide peak attributes. Mol Cell Proteomics 2010, 9:2704-2718.
48. Griffin N.M., Yu J., Long F., Oh P., Shore S., Li Y., et al. Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol 2010, 28:83-89.
49. Fang R., Elias D.A., Monroe M.E., Shen Y., McIntosh M., Wang P., et al. Differential label-free quantitative proteomic analysis of Shewanella oneidensis cultured under aerobic and suboxic conditions by accurate mass and time tag approach. Mol Cell Proteomics 2006, 5:714-725.
50. Diz A.P., Carvajal-Rodriguez A., Skibinski D.O. Multiple hypothesis testing in proteomics: a strategy for experimental work. Mol Cell Proteomics 2011, 10. [M110 004374].
51. Karp N.A., McCormick P.S., Russell M.R., Lilley K.S. Experimental and statistical considerations to avoid false conclusions in proteomics studies using differential in-gel electrophoresis. Mol Cell Proteomics 2007, 6:1354-1364.
52. Margolin A.A., Ong S.E., Schenone M., Gould R., Schreiber S.L., Carr S.A., et al. Empirical Bayes analysis of quantitative proteomics experiments. PLoS One 2009, 4:e7454.
53. Fallah-Tafti A., Foroumadi A., Tiwari R., Shirazi A.N., Hangauer D.G., Bu Y., et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem 2011, 46:4853-4858.
54. Michael J., Ciesielski S.A.M., Hangauer David G., Dyster Lyn M., Clements James L., Barnett Allen, et al. KX02, a novel therapeutic for glioma. 101st AACR Annual Meeting (Abstract #5598) 2010, [Washington, DC].
55. Pienta K.J., Replogle T., Lehr J.E. Inhibition of prostate cancer growth by vinblastine and tamoxifen. Prostate 1995, 26:270-274.
56. Tashiro E., Simizu S., Takada M., Umezawa K., Imoto M. Caspase-3 activation is not responsible for vinblastine-induced Bcl-2 phosphorylation and G2/M arrest in human small cell lung carcinoma Ms-1 cells. Jpn J Cancer Res 1998, 89:940-946.
57. Kovacevic Z., Richardson D.R. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 2006, 27:2355-2366.
58. Hermann A., Donato R., Weiger T.M., Chazin W.J. S100 calcium binding proteins and ion channels. Front Pharmacol 2012, 3:67.
59. Rehman I., Cross S.S., Azzouzi A.R., Catto J.W., Deloulme J.C., Larre S., et al. S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 2004, 91:739-744.
60. Duflos A., Kruczynski A., Barret J.M. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem 2002, 2:55-70.
61. Ben-Ze'ev A., Farmer S.R., Penman S. Mechanisms of regulating tubulin synthesis in cultured mammalian cells. Cell 1979, 17:319-325.
62. Pittenger M.F., Cleveland D.W. Retention of autoregulatory control of tubulin synthesis in cytoplasts: demonstration of a cytoplasmic mechanism that regulates the level of tubulin expression. J Cell Biol 1985, 101:1941-1952.
63. Sen A., O'Malley K., Wang Z., Raj G.V., Defranco D.B., Hammes S.R. Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem 2010, 285:28787-28795.
64. Rothschild B.L., Shim A.H., Ammer A.G., Kelley L.C., Irby K.B., Head J.A., et al. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 2006, 66:8017-8025.
65. Lv J., Liu H., Wang Q., Tang Z., Hou L., Zhang B. Molecular cloning of a novel human gene encoding histone acetyltransferase-like protein involved in transcriptional activation of hTERT. Biochem Biophys Res Commun 2003, 311:506-513.
66. Shen Q., Zheng X., McNutt M.A., Guang L., Sun Y., Wang J., et al. NAT10, a nucleolar protein, localizes to the midbody and regulates cytokinesis and acetylation of microtubules. Exp Cell Res 2009, 315:1653-1667.
67. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006, 66:5977-5980.
68. Biondo P.D., Brindley D.N., Sawyer M.B., Field C.J. The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr Biochem 2008, 19:787-796.